ImmuPharma launches regulatory push for Kapiglucagon diabetes drug

ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery company, has kicked off the regulatory groundwork needed to advance its Kapiglucagon diabetes programme towards human trials in the United States. The company has engaged tranScrip Limited, a specialist pharmaceutical consultancy, to develop its regulatory strategy and prepare for a pre-IND (investigational new drug) meeting with the US Food and Drug Administration (FDA).